APE1/Ref-1 as a Serological Biomarker for the Detection of Bladder Cancer.
- Author:
Ju Hyun SHIN
1
;
Sunga CHOI
;
Yu Ran LEE
;
Myoung Soo PARK
;
Yong Gil NA
;
Kaikobad IRANI
;
Sang Do LEE
;
Jin Bong PARK
;
Jin Man KIM
;
Jae Sung LIM
;
Byeong Hwa JEON
Author Information
- Publication Type:Original Article
- Keywords: Apurinic/apyrimidinic endonuclease 1/redox factor-1; Urinary bladder neoplasms; Biological markers; Enzyme-linked immunosorbent assay
- MeSH: Biological Markers; Drug Therapy; Enzyme-Linked Immunosorbent Assay; Humans; Radiotherapy; Recurrence; ROC Curve; Sensitivity and Specificity; Urinary Bladder Neoplasms*; Urinary Bladder*
- From:Cancer Research and Treatment 2015;47(4):823-833
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctional protein that shows elevated expression in a number of cancers. We attempted to determine whether serum APE1/Ref-1 is elevated in patients with bladder cancer. MATERIALS AND METHODS: Serum APE1/Ref-1 levels were determined using enzyme-linked immunosorbent assay in serum from patients with bladder cancer who had not received chemotherapy or radiotherapy (n=51) and non-tumor controls (n=55). The area under the receiver operating characteristic area under the curve was applied to determine the correlation between clinical factors and the serum levels of APE1/Ref-1. RESULTS: Serum levels of APE1/Ref-1 in bladder cancer patients were significantly elevated compared to those of the control group (3.548+/-0.333 ng/100 muL [n=51] for bladder cancer vs. 1.547+/-0.319 ng/100 muL [n=55] for the control group), with a sensitivity and specificity of 93% and 59%, respectively. Serum APE1/Ref-1 levels are associated with tumor stage, grade, muscle invasion, and recurrence. CONCLUSION: Serum APE1/Ref-1 might be useful as a potential serologic biomarker for bladder cancer.
